Laurus Labs receives USFDA approvals for ANDAs TLE 400 and TLE 600 tablets

Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010) Laurus Labs Ltd is pleased to announce that the Company has received an approval from USFDA under PEPFAR (President's Emergency Plan for AIDS Relief) for two ANDAs (Abbreviated New Drug Application) TLE 400 (Tenofovir/ Lamivudine/ Efavirenz - 300/300/400mg) and TLE 600 (Tenofovir/ Lamivudine/ Efavirenz - 300/300/600mg) tablets.

Laurus Labs is one of the few players in the ARV segment to receive an approval for TLE 400 tablets. TLE 400 is one of the most preferred regimens in the ARV first line treatment. The Company already received WHO Pre-Qualification for TLE 400 (Tenofovir/ Lamivudine/ Efavirenz - 300/300/400mg)

These approvals enables Laurus Labs to launch both the products in several LMIC markets.

Shares of Laurus Labs Ltd was last trading in BSE at Rs.442.25 as compared to the previous close of Rs. 425.75. The total number of shares traded during the day was 78672 in over 3695 trades.

The stock hit an intraday high of Rs. 457 and intraday low of 430.5. The net turnover during the day was Rs. 35169378.

Source : Equity Bulls

Keywords